Paclitaxel nanopolymer - Samyang

Drug Profile

Paclitaxel nanopolymer - Samyang

Alternative Names: Paclitaxel PNP

Latest Information Update: 16 Jul 2016

Price : $50

At a glance

  • Originator Samyang Biopharmaceuticals Corporation
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Mitosis inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Cancer in South Korea
  • 01 Aug 2012 Nanopolymer paclitaxel is available for licensing worldwide as of 01 Aug 2012. http://www.samyangbiopharm.com
  • 01 Aug 2012 Preclinical trials in Cancer in South Korea (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top